Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Biotechnology & Medical Research

Market Closed - Nyse 21:00:02 09/09/2024 BST 5-day change 1st Jan Change
188.16 USD +0.11% Intraday chart for Charles River Laboratories International, Inc. -4.85% -20.41%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Transcript : Charles River Laboratories International, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 09:15 AM
Charles River Laboratories, Insightec Collaborate on Focused Ultrasound in Neuroscience MT
Charles River Laboratories International, Inc. and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience CI
Mizuho Adjusts Price Target on Charles River Laboratories International to $210 From $235, Maintains Neutral Rating MT
Charles River Laboratories International Insider Sold Shares Worth $354,861, According to a Recent SEC Filing MT
TD Cowen Adjusts Price Target on Charles River Laboratories International to $203 From $228, Maintains Hold MT
Morgan Stanley Cuts Price Target on Charles River Laboratories International to $215 From $235 MT
Stephens Adjusts Price Target on Charles River Laboratories International to $240 From $250 MT
UBS Adjusts Charles River Laboratories International Price Target to $240 From $290, Maintains Buy Rating MT
Jefferies Adjusts Price Target on Charles River Laboratories International to $196 From $226 MT
Citigroup Adjusts Price Target on Charles River Laboratories International to $215 From $250 MT
Barclays Adjusts Price Target on Charles River Laboratories International to $210 From $230 MT
Goldman Sachs Adjusts Price Target on Charles River Laboratories International to $250 From $290 MT
Nasdaq's wild mood swings Our Logo
Baird Downgrades Charles River Laboratories International to Neutral From Outperform, Adjusts PT to $191 From $239 MT
JPMorgan Downgrades Charles River Laboratories International to Neutral From Overweight, Adjusts PT to $205 From $270 MT
Baird Downgrades Charles River Laboratories International to Neutral From Outperform, Adjusts PT to $191 From $239 MT
Analyst recommendations: Chevron, Fortinet, Hilton, Walt Disney, Hiscox... Our Logo
Charles River cuts 2024 forecast on lower demand for drug development services RE
Tech surge, BOJ's dovish comments boost Wall Street RE
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $240 From $300 MT
Charles River Laboratories International to Seeks Strategic Acquisitions CI
Transcript : Charles River Laboratories International, Inc., Q2 2024 Earnings Call, Aug 07, 2024
Charles River cuts 2024 forecast as funding crunch among biotech clients persists RE
Charles River Laboratories' Q2 Non-GAAP Earnings Rise, Revenue Falls; 2024 Outlook Slashed MT
Chart Charles River Laboratories International, Inc.
More charts
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (63.4%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (19.2%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (17.5%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (83.3%) and sales of products (16.7%). Net sales are distributed geographically as follows: the United States (56.8%), Europe (26%), Canada (11.8%), Asia/Pacific (4.9%) and other (0.4%).
Employees
21,100
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
188.16USD
Average target price
224.07USD
Spread / Average Target
+19.09%
Consensus
  1. Stock Market
  2. Equities
  3. CRL Stock
  4. News Charles River Laboratories International, Inc.
  5. Charles River Laboratories International Insider Sold Shares Worth $354,861, According to a Recent SEC Filing
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW